Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Doxazosin Mesylate

FDA-approved product (tablet, oral), marketed as Cardura, Cardura Xl, Doxazosin Mesylate.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Doxazosin Mesylate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Benign prostatic hyperplasia
  • Hypertension
  • Myocardial infarction

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Alpha-adrenoreceptor antagonists
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA60.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli58.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae36.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis58.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Doxazosin Mesylate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.6 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Doxazosin Mesylate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Cyclooxygenase-2 (COX-2) Inhibitor Reduces Serum Prostatic Specific Antigen (PSA) Levels

    NCT01678313 · start 2012-08

    Registered record
    Registry ID
    NCT01678313
    Conditions
    Benign Prostatic Hyperplasia
    Interventions
    Doxazosin 4 mg daily plus Celecoxib 200 mg every day (QD); Doxazosin 4 mg every day (QD)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-08
    Completion
    2013-08
    Enrolment
    140

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBenign Prostatic Hyperplasia
    InterventionDoxazosin 4 mg daily plus Celecoxib 200 mg every day (QD); Doxazosin 4 mg every day (QD)
    PhasePhase 2
    Registry statusCompleted

  • Impact of Renal Anatomy on Shock Wave Lithotripsy Outcomes for Lower Pole Kidney Stones

    NCT01589484 · start 2012-04

    Registered record
    Registry ID
    NCT01589484
    Conditions
    Urolithiasis; Urinary Lithiasis; Kidney Calculi
    Interventions
    SWL - Compact Delta Dornier Med Tech
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2012-04
    Completion
    2014-12
    Enrolment
    104

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionUrolithiasis; Urinary Lithiasis; Kidney Calculi
    InterventionSWL - Compact Delta Dornier Med Tech
    PhaseNot applicable
    Registry statusCompleted

  • DOXAZOSIN FOR PTSD

    NCT02308202 · start 2012-01

    Registered record
    Registry ID
    NCT02308202
    Conditions
    PTSD
    Interventions
    doxazosin; Perindopril; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-01
    Completion
    2014-06-30
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPTSD
    Interventiondoxazosin; Perindopril; Placebo
    PhasePhase 1
    Registry statusCompleted

  • Phenoxybenzamine Versus Doxazosin in PCC Patients

    NCT01379898 · start 2011-12

    Registered record
    Registry ID
    NCT01379898
    Conditions
    Pheochromocytoma
    Interventions
    Phenoxybenzamine; Doxazosin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-12
    Completion
    2018-01
    Enrolment
    134

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPheochromocytoma
    InterventionPhenoxybenzamine; Doxazosin
    PhasePhase 4
    Registry statusCompleted

  • Doxazosin an a1 Antagonist for Alcohol Dependence

    NCT01437046 · start 2011-11-01

    Registered record
    Registry ID
    NCT01437046
    Conditions
    Alcohol Dependence; Anxiety
    Interventions
    Doxazosin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2011-11-01
    Completion
    2015-03-01
    Enrolment
    41

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlcohol Dependence; Anxiety
    InterventionDoxazosin; Placebo
    PhaseEarly phase 1
    Registry statusCompleted

  • Bioequivalence Study of Doxazosin 4 Mg Orally-Disintegrating Tablet With Or Without Water To Doxazosin 4 Mg Japanese Marketed Immediate Release Tablet Under Fasted Condition

    NCT01389609 · start 2011-07

    Registered record
    Registry ID
    NCT01389609
    Conditions
    Hypertension
    Interventions
    Doxazosin 4 mg Japanese marketed IR tablet; Doxazosin 4 mg ODT with water; Doxazosin 4 mg ODT without water
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-07
    Completion
    2011-08
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionDoxazosin 4 mg Japanese marketed IR tablet; Doxazosin 4 mg ODT with water; Doxazosin 4 mg ODT without water
    PhasePhase 1
    Registry statusCompleted

  • Doxazosin and Ramipril in Hypertension

    NCT02901977 · start 2011-03

    Registered record
    Registry ID
    NCT02901977
    Conditions
    Hypertension
    Interventions
    Ramipril; Doxazosin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-03
    Completion
    2015-04
    Enrolment
    71

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension
    InterventionRamipril; Doxazosin
    PhasePhase 4
    Registry statusCompleted

  • Evaluating the Impact of Early Versus Delayed 5 Alpha Reductase Inhibitor Treatment on the Risk of Emergent Surgery in Men With Benign Prostatic Hyperplasia

    NCT01332487 · start 2010-08

    Registered record
    Registry ID
    NCT01332487
    Conditions
    Prostatic Hyperplasia
    Interventions
    5ARI + AB
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2010-08
    Completion
    2010-08
    Enrolment
    4,068

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Hyperplasia
    Intervention5ARI + AB
    PhaseNot recorded
    Registry statusCompleted

  • Clinical Progression and Costs in Benign Prostatic Hyperplasia Patients Treated With Early Versus Delayed Combination Therapy

    NCT01435954 · start 2010-08

    Registered record
    Registry ID
    NCT01435954
    Conditions
    Benign Prostatic Hyperplasia
    Interventions
    Early combination therapy; Delayed combination therapy
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2010-08
    Completion
    2011-03
    Enrolment
    13,551

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBenign Prostatic Hyperplasia
    InterventionEarly combination therapy; Delayed combination therapy
    PhaseNot recorded
    Registry statusCompleted

  • Benign Prostatic Hypertrophy Treatment Patterns & Outcomes: Marketscan

    NCT01323998 · start 2010-04

    Registered record
    Registry ID
    NCT01323998
    Conditions
    Prostatic Hyperplasia
    Interventions
    5ARI; AB
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2010-04
    Completion
    2010-06
    Enrolment
    35,032

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Hyperplasia
    Intervention5ARI; AB
    PhaseNot recorded
    Registry statusCompleted

  • Pharmacogenetics of Doxazosin for Cocaine Dependence

    NCT01145183 · start 2010-03

    Registered record
    Registry ID
    NCT01145183
    Conditions
    Cocaine Dependence
    Interventions
    Doxazosin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-03
    Completion
    2015-09
    Enrolment
    96

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCocaine Dependence
    InterventionDoxazosin; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Dutasteride in Enlarged Prostate Economic Assessment: A Retrospective Database Pooled Analysis of Early 5-alpha Reductase Inhibitor Use

    NCT01332435 · start 2009-11

    Registered record
    Registry ID
    NCT01332435
    Conditions
    Prostatic Hyperplasia
    Interventions
    5ARI + AB
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2009-11
    Completion
    2010-01
    Enrolment
    6,896

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Hyperplasia
    Intervention5ARI + AB
    PhaseNot recorded
    Registry statusCompleted

  • Combination Treatment With Doxazosin Plus TolterodineSR 2 mg Versus 4mg in Men With an Overactive Bladder (OAB) and Benign Prostatic Hyperplasia (BPH)

    NCT00922506 · start 2009-05

    Registered record
    Registry ID
    NCT00922506
    Conditions
    Overactive Bladder; Benign Prostatic Hyperplasia
    Interventions
    doxazosin plus tolterodine SR
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-05
    Completion
    2014-06
    Enrolment
    83

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOveractive Bladder; Benign Prostatic Hyperplasia
    Interventiondoxazosin plus tolterodine SR
    PhasePhase 4
    Registry statusCompleted

  • Establishing Predictors of Enlarged Prostate Treatment Adherence: Linking Symptom Improvement to Adherence

    NCT01390870 · start 2009-05

    Registered record
    Registry ID
    NCT01390870
    Conditions
    Prostatic Hyperplasia
    Interventions
    5ARI or AB or Combination Therapy (5ARI + AB)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2009-05
    Completion
    2010-09
    Enrolment
    400

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Hyperplasia
    Intervention5ARI or AB or Combination Therapy (5ARI + AB)
    PhaseNot recorded
    Registry statusCompleted

  • Optimum Treatment for Drug-Resistant Hypertension

    NCT02369081 · start 2009-05

    Registered record
    Registry ID
    NCT02369081
    Conditions
    Hypertension, Resistant to Conventional Therapy
    Interventions
    Spironolactone; Bisoprolol; Doxazosin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2009-05
    Completion
    2015-08
    Enrolment
    348

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypertension, Resistant to Conventional Therapy
    InterventionSpironolactone; Bisoprolol; Doxazosin; Placebo
    PhasePhase 4
    Registry statusUnknown